Bayer Faces Two Clocks: A Pending Settlement and a November Earnings Test

Bayer investors are juggling two separate timelines that rarely move in step. One is legal: a proposed $7.25 billion glyphosate settlement is still awaiting approval, according to media reports circulated midweek. The other is operational: third-quarter 2026 results are due on November 3, when the market will finally see whether the company's pharmaceutical momentum is translating into the bottom line.

Confusing the two would overstate what either piece of news actually tells you. Business progress and analyst enthusiasm do nothing to resolve the approval condition hanging over the settlement. By the same token, the status of the legal deal says nothing about whether Bayer will hit its own operating targets.

Two Banks, Two Price Tags, One Cautious Profit View

JPMorgan reaffirmed its "Overweight" rating on Tuesday, keeping a price target of 61 euros. Analyst Richard Vosser pointed to an expected confirmation of the annual guidance as a potential source of confidence. His read on the upcoming numbers, though, is mixed rather than uniformly bullish.

On revenue, Vosser projects a figure 2% above the consensus estimate. For EBITDA, he expects the opposite — 6% below consensus. That gap matters: a revenue beat would not automatically translate into stronger earnings, and the distinction will be central when the quarterly statement lands.

UBS weighed in two days later with a buy recommendation of its own, holding its target at 62 euros. The Swiss bank flagged the well-known weakness in the agricultural division while pointing to intact trends through fiscal 2026 and 2027, and it continues to see momentum in pharmaceuticals. Notably, its positive stance does not rest on the farm business having already turned the corner.

Pipeline News Covers Several Stages, Not One Finish Line

Recent pharmaceutical announcements offer evidence of development potential, but they sit at very different points along the road to broader use. Roughly a week ago, Bayer subsidiary Vividion launched a global Phase II trial of VVD-214 in combination with pembrolizumab, dosing its first patient. The study enrolls previously untreated patients with advanced MSI-H or dMMR colorectal cancer. Vividion is wholly owned by Bayer and operates independently. Starting the trial advances the clinical program — it is not proof of efficacy from this study, nor anything close to an approval.

Finerenon, marketed by Bayer as Kerendia, sits at a later stage. About a week ago the US Food and Drug Administration accepted a supplemental application for chronic kidney disease without diabetes, backed by positive results from the Phase III FIND-CKD study. Acceptance is a regulatory step forward, not a green light for the requested indication.

What November 3 Can and Cannot Settle

The quarterly release gives investors the next concrete occasion to test the pharma narrative and the acknowledged agricultural drag against actual figures. What it will not do is resolve the glyphosate question, which remains on its own track regardless of how the quarter turns out. Regulatory milestones, operating expectations and legal risk each deserve a separate ledger — and the expected guidance confirmation is, after all, an analyst assumption rather than anything the company has said.